BRITISH JOURNAL OF HAEMATOLOGY

Volume 114, Issue 1, July 2001

1 **EDITORIAL**

IMAGES IN HAEMATOLOGY

2 **Normal fetal bone**
J. E. Allen

3 **Hepatosplenic T-cell lymphoma**
V. Franco and A. M. Florena

REVIEWS

4 **Congenital α_2-plasmin inhibitor deficiencies: a review**
R. Favier, N. Aoki and P. de Moerloose

11 **Non-MHC-restricted cytotoxic cells: their roles in the control and treatment of leukaemias**
M. W. Lowdell, L. Lamb, C. Hoyle, A. Velardi and H. G. Prentice

ANNOTATION

25 **Does red-cell T activation matter?**
A. F. Eder and C. S. Manno

HAEMATOLOGICAL MALIGNANCY

31 **Relationship between graft-versus-host disease and graft-versus-leukaemia in partial T cell-depleted bone marrow transplantation**
H. M. van der Straaten, R. Fijnheer, A. W. Dekker, H. K. Nieuwenhuis and L. F. Verdonck

36 **HLA-A3 increases and HLA-DR1 decreases the risk of acute graft-versus-host disease after HLA-matched sibling bone marrow transplantation for chronic myelogenous leukaemia**
R. E. Clark, J. Hermans, A. Madrigal, D. Nachbaur, G. Kropshofer, A. Gratwohl, J. Apperley and D. Niederwieser for the Chronic Leukaemia Working Party of the European Group of Blood and Bone Marrow Transplantation

42 **Factors affecting lymphocyte subset reconstitution after either related or unrelated cord blood transplantation in children – a Eurocord analysis**
T. Niehues, V. Rocha, A. H. Filipovich, K. W. Chan, R. Porcher, G. Michel, J. J. Ortega, P. Wernet, U. Göbel, E. Gluckman and F. Locatelli

49 ***In vivo* expansion of the endogenous B-cell compartment stimulated by radiation and serial bone marrow transplantation induces B-cell leukaemia in mice**
T. L. Holyoake, M. G. Freshney, K. Samuel, J. Ansell, G. E. Watson, E. G. Wright, G. J. Graham and I. B. Pragnell

57 ***In vitro* T-cell receptor Vβ repertoire analysis may identify which T-cell Vβ families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation**
D. E. Epperson, D. A. Margolis, L. McOlash, T. Janczak and A. J. Barrett

63 **Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis**
S. Kamihira, Y. Yamada, Y. Hirakata, M. Tomonaga, K. Sugahara, T. Hayashi, N. Dateki, H. Harasawa and K. Nakayama

70 **Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia**
C. Pepper, A. Thomas, T. Hoy, C. Fegan and P. Bentley

78 **Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia**
G. Barosi, A. Grossi, B. Comotti, P. Musto, G. Gamba and M. Marchetti

84 **Antisense oligodeoxynucleotides to latent membrane protein 1 induce growth inhibition, apoptosis and Bcl-2 suppression in Epstein-Barr virus (EBV)-transformed B-lymphoblastoid cells, but not in EBV-positive natural killer cell lymphoma cells**
T. Noguchi, K. Ikeda, K. Yamamoto, I. Yoshida, A. Ashiba, J. Tsuchiyama, K. Shinagawa, T. Yoshino, M. Takata and M. Harada

93 **Clinical significance of *Aspergillus* fungaemia in patients with haematological malignancies and invasive aspergillosis**
C. Girmenia, M. Nucci and P. Martino

Short reports

99 **Pretreatment characteristics and clinical outcome of acute promyelocytic leukaemia patients according to the *PML-RARα* isoforms: a study of the PETHEMA group**
M. González, E. Barragán, P. Bolufer, C. Chillón, D. Colomer, R. Borstein, M. J. Calasanz, M. T. Gómez-Casares, A. Villegas, I. Marugán, J. Román, G. Martín, C. Rayón, G. Debén, M. Tormo, J. Díaz-Mediavilla, J. Esteve, J. González-San Miguel, C. Rivas, K. Pérez-Equiza, R. García-Sanz, F. J. Capote, J. M. Ribera, J. Arias, A. León and M. A. Sanz for the Spanish Programme for the Study and Treatment of Haematological Malignancies (PETHEMA) Group

104 **Clearance of maternal leukaemic cells in a neonate**
V. H. J. van der Velden, M. J. Willemse, M. F. Mulder, T. Szczepański, A. W. Langerak, J. M. Wijkhuijs and J. J. M. van Dongen

107 **Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia**
M. Sinisalo, J. Aittoniemi, P. Oivanen, H. Käyhty, R.-M. Ölander and J. Vilpo

111 **A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia**
R. A. Mesa, A. Tefferi, M. A. Elliott, H. C. Hoagland, T. G. Call, G. S. Schroeder, S.-Y. Yoon, C.-Y. Li, L. A. Gray, S. Margolin and C. C. Hook

PLATELETS, HAEMOSTASIS AND THROMBOSIS

114 **High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system**
M. Kjalke, M. Ezban, D. M. Monroe, M. Hoffman, H. R. Roberts and U. Hedner

121 **Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy**
M. C. Kappers-Klunne and M. B. van't Veer

126 **The role of thrombopoietin in post-operative thrombocytosis**
C. C. Folman, M. Ooms, B. Kuenen B, S. M. de Jong, R. J. W. M. Vet, M. de Haas and A. E. G. Kr. von dem Borne

134 **RAFTK/Pyk2 involvement in platelet activation is mediated by phosphoinositide 3-kinase**
K. Koziak, E. Kaczmarek, S. Y. Park, Y. Fu, S. Avraham and H. Avraham

141 **Bruton's tyrosine kinase is present in normal platelets and its absence identifies patients with X-linked agammaglobulinaemia and carrier females**
T. Futatani, C. Watanabe, Y. Baba, S. Tsukada and H. D. Ochs

150 **The C807T/G873A polymorphism in the platelet glycoprotein Ia gene and the risk of acute coronary syndrome in the Italian population**
I. Casorelli, V. De Stefano, A. M. Leone, P. Chiusolo, F. Burzotta, K. Paciaroni, E. Rossi, F. Andreotti, G. Leone and A. Maseri

155 **Decreased fibrinolytic potential in South Asian women with ischaemic cerebrovascular disease**
K. Kain, A. J. Catto, A. M. Carter, J. Young, J. Bamford, J. Bavington and P. J. Grant

162 **Post-menopausal hormone therapy and concentrations of protein C and antithrombin in elderly women**
M. Cushman, B. M. Psaty, E. N. Meilahn, A. S. Dobs and L. H. Kuller

169 **Protein Z in ischaemic stroke**
K. Kobelt, F. D. Biasiutti, H. P. Mattle, B. Lämmle and W. A. Wuillemin

Short report 174 **Successful treatment of severe intra-abdominal bleeding associated with disseminated intravascular coagulation using recombinant activated factor VII**
F. Moscardó, F. Pérez, J. de la Rubia, B. Balerdi, J. I. Lorenzo, M. L. Senent, I. Aznar, S. Carceller and M. A. Sanz

LEUCOCYTES

177 **Evidence that natural killer cells express mini P-glycoproteins but not classic 170 kDa P-glycoprotein**
C. Trambas, Z. Wang, M. Cianfriglia and G. Woods

185 **^{99m}Tc-HMPAO (Ceretec) is stored in and released from the granules of eosinophil granulocytes**
L. Moberg, M. Karawajczyk and P. Venge

191 **Profiling of genes expressed in human monocytes and monocyte-derived dendritic cells using cDNA expression array**
N. Lapteva, Y. Ando, M. Nieda, H. Hohjoh, M. Okai, A. Kikuchi, G. Dymshits, Y. Ishikawa, T. Juji and K. Tokunaga

Short report 198 **Autoimmune neutropenia in pregnant women causing neonatal neutropenia**
J. Kameoka, T. Funato, T. Miura, H. Harigae, J. Saito, H. Yokoyama, S. Takahashi, M. Yamada, O. Sasaki, M. Imaizumi, N. Takata, K. Meguro and T. Sasaki

HAEMOPOIESIS

201 **An *in situ* study of CD34$^+$ cells in human fetal bone marrow**
J. E. Allen and D. L. Henshaw

211 **Variables to predict engraftment of umbilical cord blood into immunodeficient mice: usefulness of the non-obese diabetic–severe combined immunodeficient assay**
K. K. Ballen, H. Valinski, D. Greiner, L. D. Shultz, P. S. Becker, C. C. Hsieh, F. M. Stewart and P. J. Quesenberry

RED CELLS

219 **Analysis of chimaerism in thalassaemic children undergoing stem cell transplantation**
P. J. Amrolia, T. Vulliamy, G. Vassiliou, S. Lawson, J. Bryon, J. Kaeda, I. Dokal, R. Johnston, P. Veys, P. Darbyshire and I. A. G. Roberts

Short reports 226 **Reduced serum ceruloplasmin levels in hereditary haemochromatosis**
G. Cairo, D. Conte, L. Bianchi, M. Fraquelli and S. Recalcati

230 **Haemolytic onset of Wilson disease in a patient with homozygous truncation of ATP7B at Arg1319**
M. Prella, R. Baccalà, J.-D. Horisberger, D. Belin, F. Di Raimondo, R. Invernizzi, R. Garozzo and M. Schapira

TRANSFUSION

233 **The effect of leucocyte depletion on the quality of fresh-frozen plasma**
R. Cardigan, J. Sutherland, M. Garwood, P. Krailadsiri, J. Seghatchian, M. Beard, N. Beckman and L. M. Williamson

CORRESPONDENCE

241 **Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with α-interferon: comments**
M. Pfirrmann and J. Hasford
242 **Reply to Pfirrmann and Hasford**
F. Bonifazi, A. de Vivo, G. Rosti, M. Tiribelli, D. Russo, E. Trabacchi, M. Fiacchini, E. Montefusco and M. Baccarani on behalf of the Italian Cooperative Study Group on Chronic Myeloid Leukaemia
243 **TFR2 Y250X mutation in Italy**
M. De Gobbi, M. R. Barilaro, G. Garozzo, L. Sbaiz, F. Alberti and C. Camaschella
244 **Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)**
N. Ahrens, D. Kingreen, A. Seltsam and A. Salama
245 **Thalidomide and low-dose dexamethasone in myeloma treatment**
B. Myers, C. Grimley and G. Dolan
245 **Use of recombinant factor VIIa for post-operative haemorrhage in a patient with Glanzmann's thrombasthenia and human leucocyte antigen antibodies**
R. K. Patel, G. F. Savidge and S. Rangarajan

Volume 114, Issue 2, August 2001

IMAGES IN HAEMATOLOGY

247 **Howell Jolly bodies and a history of home-made bread**
A. Wiestner, A. Tichelli and A. Gratwohl
248 **Reactive haemophagocytosis as a consequence of gluten enteropathy-associated intestinal non-Hodgkin's lymphoma with fatal outcome**
C. J. Mainwaring, C. M. James, F. Pidgeon and S. Webb

REVIEW

249 **The dysfibrinogenaemias**
H. R. Roberts, T. E. Stinchcombe and D. A. Gabriel

HISTORICAL REVIEW

258 **Venous thrombosis and anticoagulant therapy**
P. M. Mannucci and L. Poller

ANNOTATION

271 **The management of coumarin-induced over-anticoagulation**
M. Makris and H. G. Watson

HAEMATOLOGICAL MALIGNANCY

281 **Quantification of TEL–AML1 transcript for minimal residual disease assessment in childhood acute lymphoblastic leukaemia**
S. Drunat, M. Olivi, G. Brunie, B. Grandchamp, E. Vilmer, I. Bièche and H. Cavé

290 **Significance of angiogenin plasma concentrations in patients with acute myeloid leukaemia and advanced myelodysplastic syndrome**
S. Verstovsek, H. Kantarjian, A. Aguayo, T. Manshouri, E. Freireich, M. Keating, E. Estey and M. Albitar

296 **Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation *in vitro***
H. Sutherland, A. Blair, S. Vercauteren and R. Zapf

307 **Microsatellite instability occurs in defined subsets of patients with acute myeloblastic leukaemia**
E. P. Das-Gupta, C. H. Seedhouse and N. H. Russell

313 **Fluorescent 5′-exonuclease assay for the absolute quantification of Wilms' tumour gene (WT1) mRNA: implications for monitoring human leukaemias**
K.-A. Kreuzer, A. Saborowski, J. Lupberger, C. Appelt, I.-K. Na, P. le Coutre and C. A. Schmidt

319 **Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study**
E. Vellenga, M. van Agthoven, A. J. Croockewit, L. F. Verdonck, P. J. Wijermans, M. H. J. van Oers, C. P. Volkers, G. W. van Imhoff, T. Kingma, C. A. Uyl-de Groot and W. E. Fibbe

327 **Deletions of D13S25, D13S319 and *RB-1* mapping to 13q14.3 in T-cell prolymphocytic leukaemia**
V. Brito-Babapulle, M. Baou, E. Matutes, R. Morilla, S. Atkinson and D. Catovsky

333 **Intensification of salvage treatment with high-dose sequential chemotherapy improves the outcome of patients with refractory or relapsed aggressive non-Hodgkin's lymphoma**
S. Cortelazzo, A. Rambaldi, A. Rossi, E. Oldani, M. Ghielmini, F. Benedetti, C. Tarella, F. Zaglio, U. Vitolo, M. Di Nicola, E. Pogliani, F. Cavalli, A. M. Gianni and T. Barbui

342 **Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group**
M. Hallek, B. Schmitt, M. Wilhelm, R. Busch, A. Kröber, H.-P. Fostitsch, O. Sezer, M. Herold, W. Knauf, C. M. Wendtner, R. Kuse, M. Freund, A. Franke, F. Schriever, C. Nerl, H. Döhner, E. Thiel, W. Hiddemann, G. Brittinger, B. Emmerich and the German Chronic Lymphocytic Leukaemia Study Group

349 **Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-AZA-2′-deoxycytidine**
M. Lübbert, P. Wijermans, R. Kunzmann, G. Verhoef, A. Bosly, C. Ravoet, M. Andre and A. Ferrant

Short reports

358 **Successful treatment with cyclosporin A for myelodysplastic syndrome with erythroid hypoplasia associated with T-cell receptor gene rearrangements**
T. Shimamoto, T. Iguchi, K. Ando, T. Katagiri, T. Tauchi, Y. Ito, M. Yaguchi, K. Miyazawa, Y. Kimura, M. Masuda, H. Mizoguchi and K. Ohyashiki

362 **Analysis of *FGFR3* gene mutations in multiple myeloma patients with t(4;14)**
D. Intini, L. Baldini, S. Fabris, L. Lombardi, G. Ciceri, A. T. Maiolo and A. Neri

365 **Philadelphia (Ph) chromosome-positive chronic myeloid leukaemia relapsing as Ph-negative leukaemia after allogeneic bone marrow transplantation**
W. Y. Au, A. K. W. Lie, S. K. Ma, T. S. K. Wan, R. Liang, Y. H. Leung and Y. L. Kwong

PLATELETS, HAEMOSTASIS AND THROMBOSIS

369 **Severe factor VII deficiency with recurrent intracranial haemorrhages owing to double heterozygosity for a splice site mutation of an IVS4 and a novel nonsense mutation in exon 8 (Gln211→Term)**
O. Takamiya and Y. Okimoto

375 **Anti-tissue factor pathway inhibitor activity in patients with primary antiphospholipid syndrome**
M. J. Adams, S. Donohoe, I. J. Mackie and S. J. Machin

380 **High factor VIII levels contribute to the thrombotic risk in families with factor V Leiden**
R. Lensen, R. M. Bertina, J. P. Vandenbroucke and F. R. Rosendaal

387 **The effect of human platelet alloantigen polymorphisms on the *in vitro* responsiveness to adrenaline and collagen**
I. Theodoropoulos, C. Christopoulos, P. Metcalfe, E. Dimitriadou, P. Economopoulos and D. Loucopoulos

Short reports

394 **Heparin-induced thrombocytopenia and thrombosis syndrome: *in vivo* cross-reactivity with danaparoid and successful treatment with r-Hirudin**
T. B. Keng and B. H. Chong

397 **Rapid genotyping of human platelet antigen 5 with fluorophore-labelled hybridization probes on the LightCycler**
E. Kretzschmar, N. Von Ahsen and H. Trobisch

LEUCOCYTES

400 **Persistent polyclonal B-cell lymphocytosis is an expansion of functional IgD^+CD27^+ memory B cells**
A. Himmelmann, O. Gautschi, M. Nawrath, U. Bolliger, J. Fehr and R. A. Stahel

406 **Growth and immortalization of human myeloma cells in immunodeficient severe combined immunodeficiency mice: a preclinical model**
T. Rème, E. Gueydon, C. Jacquet, B. Klein and J. Brochier

414 **Evidence of a role for a non-matrix-type metalloproteinase activity in the shedding of syndecan-1 from human myeloma cells**
I. Holen, N. L. Drury, P. G. Hargreaves and P. I. Croucher

HAEMOPOIESIS

422 **A prospective analysis of the pattern of immune reconstitution in a paediatric cohort following transplantation of positively selected human leucocyte antigen-disparate haematopoietic stem cells from parental donors**
M. Eyrich, P. Lang, S. Lal, P. Bader, R. Handgretinger, T. Klingebiel, D. Niethammer and P. G. Schlegel

433 **Prolonged *ex vivo* culture of cord blood $CD34^+$ cells facilitates myeloid and megakaryocytic engraftment in the non-obese diabetic severe combined immunodeficient mouse model**
A. M. Rice, J. A. Wood, C. G. Milross, C. J. Collins, J. Case, M. R. Vowels and R. E. Nordon

444 **Transcript profiling of human dendritic cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble CD40 ligand trimer and interferon gamma**
F. Moschella, A. Maffei, R. P. Catanzaro, K. P. Papadopoulos, D. Skerrett, C. S. Hesdorffer and P. E. Harris

458 **Cord blood megakaryocytes do not complete maturation, as indicated by impaired establishment of endomitosis and low expression of G1/S cyclins upon thrombopoietin-induced differentiation**
R. Bornstein, J. García-Vela, F. Gilsanz, C. Auray and C. Calés

466 **Calcium ionophore: a single reagent for the differentiation of primary human acute myelogenous leukaemia cells towards dendritic cells**
M. Waclavicek, A. Berer, L. Oehler, J. Stöckl, E. Schloegl, O. Majdic and W. Knapp

RED CELLS

474 ***HFE* mutations, iron deficiency and overload in 10 500 blood donors**
H. A. Jackson, K. Carter, C. Darke, M. G. Guttridge, D. Ravine, R. D. Hutton, J. A. Napier and M. Worwood

CORRESPONDENCE

485 **Identity of the tissue factor-inducing activity in human plasma**
G. M. Rodgers

485 **Characterization of mutant clones lacking T-cell receptor alleles in a cell line from an adult T-cell leukaemia patient**
Y. Kusunoki, S. Kyoizumi, S. Umeki, Y. Kirai and D. G. MacPhee

487 **Severe persistent neuropsychiatric toxicity after a human leucocyte antigen-non-identical peripheral blood stem cell transplantation (total body irradiation, etoposide, thiotepa) and interleukin 2-based experimental therapy for poor prognosis relapse acute lymphoblastic leukaemia**
C. F. Classen, A. S. Schulz, K.-M. Debatin and W. Friedrich

489 **Interpretation of inflammatory markers in feverish cancer patients with or without neutropenia at admission**
E. S. J. M. de Bont, C. S. M. Oude Nijhuis, W. A. Kamps and E. Vellenga

490 **Reply to de Bont *et al***
G. Fleischhack, I. Kambeck, D. Cipic, C. Hasan and U. Bode

492 **BOOK REVIEW**

493 **ANNOUNCEMENT**

Volume 114, Number 3, September-I 2001

IMAGES IN HAEMATOLOGY

495 **Endogenous erythroid colony growth in polycythaemia vera**
F. Girodon, P.-M. Carli, M. Flesch and M. Maynadie

REVIEW

496 **Novel treatment modalities: new platelet preparations and substitutes**
D. H. Lee and M. A. Blajchman

ANNOTATION

506 **Pitfalls in the diagnosis of childhood leukaemia**
J. M. Chessells

GUIDELINE

512 **Investigation and management of heritable thrombophilia**
I. D. Walker, M. Greaves and F. E. Preston

HISTORICAL REVIEW

529 **Amyloidosis: a convoluted story**
R. A. Kyle

HAEMATOLOGICAL MALIGNANCY

539 **Therapy-related acute lymphoblastic leukaemia with *MLL* rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992**
M. K. Andersen, D. H. Christiansen, B. A. Jensen, P. Ernst, G. Hauge and J. Pedersen-Bjergaard

544 **Favourable effect of the combination of acute and chronic graft-versus-host disease on the outcome of allogeneic peripheral blood stem cell transplantation for advanced haematological malignancies**
S. Brunet, A. Urbano-Ispizua, E. Ojeda, D. Ruiz, J. M. Moraleda, M. A. Díaz, D. Caballero, J. Bargay, J. de la Rubia, C. Solano, J. Zuazu, J. L. Diez, J. de la Serna, I. Espigado, A. Alegre, J. P. Torres, M. Jurado, M. Fernández, P. Vivancos, E. Carreras, F. Hernández, J. Maldonado, J. Sierra, C. Rozman for the Spanish Group of Allogeneic–PBT, Spain

551 **Acute myeloblastic leukaemias of FAB types M6 and M4, with cryptic *PML/RARα* fusion gene formation, relapsing as acute promyelocytic leukaemia M3**
A. Virchis, E. Massey, T. Butler, P. Devaraj, F. Wright, L. Secker-Walker, H. G. Prentice and A. Mehta

557 **Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy**
E. Månsson, A. Paul, C. Löfgren, K. Ullberg, C. Paul, S. Eriksson and F. Albertioni

566 **The leukaemia-associated transcription factors EVI-1 and MDS1/EVI1 repress transcription and interact with histone deacetylase**
U. Vinatzer, J. Taplick, C. Seiser, C. Fonatsch and R. Wieser

574 **Increased lactate production follows loss of mitochondrial membrane potential during apoptosis of human leukaemia cells**
M. Tiefenthaler, A. Amberger, N. Bacher, B. L. Hartmann, R. Margreiter, R. Kofler and G. Konwalinka

581 **Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1**
A. Carter, E. J. Dann, T. Katz, Y. Shechter, A. Oliven, R. Regev, E. Eytan, J. M. Rowe and G. D. Eytan

591 **Cell cycle analysis and expression of cell cycle regulator genes in myeloma cells overexpressing cyclin D1**
K. Yata, Y. Sadahira, T. Otsuki, H. Sakaguchi, Y. Isozaki, M. Uno, J. Kurebayashi, T. Fujii, S. Eda, A. Ueki, Y. Yawata, O. Yamada and T. Sugihara

600 **Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years**
A. Badros, B. Barlogie, E. Siegel, C. Morris, R. Desikan, M. Zangari, A. Fassas, E. Anaissie, N. Munshi and G. Tricot

608 **Autologous plasma activates Akt/protein kinase B and enhances basal survival and resistance to DNA damage-induced apoptosis in B-chronic lymphocytic leukaemia cells**
R. G. Wickremasinghe, K. Ganeshaguru, D. T. Jones, C. Lindsay, V. J. Spanswick, J. A. Hartley, M. Wadhwa, R. Thorpe, A. V. Hoffbrand, H. G. Prentice and A. B. Mehta

616 **Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease**
D. Molin, M. Fischer, Z. Xiang, U. Larsson, I. Harvima, P. Venge, K. Nilsson, C. Sundström, G. Enblad and G. Nilsson

624 **T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement**
E. Olavarria, F. Child, A. Woolford, S. J. Whittaker, J. G. Davis, C. McDonald, S. Chilcott, M. Spittle, R. J. Grieve, S. Stewart, J. F. Apperley and R. Russell-Jones

Short reports

632 **Mutation screening of the *c-MYB* negative regulatory domain in acute and chronic myeloid leukaemia**
J. K. Lutwyche, R. A. Keough, T. P. Hughes and T. J. Gonda

635 **E1A3 as a unique, naturally occurring BCR–ABL transcript in an indolent case of chronic myeloid leukaemia**
J. Roman, A. Jimenez, M. Barrios, J. A. Castillejo, J Maldonado and A. Torres

638 **Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis**
L. Camba, L. Aldrighetti, F. Ciceri, M. Bernardi, S. Marktel, E. Angeli and M. Giacomelli

PLATELETS, HAEMOSTASIS AND THROMBOSIS

641 **Mutations in the thrombomodulin and endothelial protein C receptor genes in women with late fetal loss**
F. Franchi, E. Biguzzi, I. Cetin, F. Facchetti, T. Radaelli, M. Bozzo, G. Pardi and E. M. Faioni

647 **Anti-prothrombin antibodies combined with lupus anticoagulant activity is an essential risk factor for venous thromboembolism in patients with systemic lupus erythematosus**
J. Nojima, H. Kuratsune, E. Suehisa, Y. Futsukaichi, H. Yamanishi, T. Machii, T. Kitani, Y. Iwatani and Y. Kanakura

655 **Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins**
R. Kaaja, V. Pettilä, P. Leinonen and O. Ylikorkala

LEUCOCYTES

660 **Activation of natural killer cells with interleukin 2 (IL-2) and IL-12 increases perforin binding and subsequent lysis of tumour cells**
C. Lehmann, M. Zeis and L. Uharek

666 **Persistent polyclonal B-cell lymphocytosis: further evidence for a genetic disorder associated with B-cell abnormalities**
R. Delage, L. Jacques, M. Massinga-Loembe, J. Poulin, D. Bilodeau, C. Mignault, P. F. Leblond and A. Darveau

671 **Cytokine production and T-cell activation by macrophage–dendritic cells generated for therapeutic use**
A. Coronel, A. Boyer, J.-D. Franssen, J.-L. Romet-Lemonne, W. H. Fridman and J.-L. Teillaud

681 **Efficient *ex vivo* generation of dendritic cells from CD14$^+$ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials**
H. Araki, N. Katayama, H. Mitani, H. Suzuki, H. Nishikawa, M. Masuya, Y. Ikuta, N. Hoshino, H. Miyashita, K. Nishii, N. Minami and H. Shiku

690 **Inhibitory effect of interleukin 3 on early development of human B-lymphopoiesis**
K. Miyamoto, K. Tsuji, T. Maekawa, S. Asano and T. Nakahata

Short report 698 **Enhanced activation of B cells in a granulocyte colony-stimulating factor-mobilized peripheral blood stem cell graft**
H. Tayebi, V. Lapierre, P. Saas, A. Lienard, L. Sutton, N. Milpied, M. Attal, J.-Y. Cahn, M. Kuentz, D. Blaise, P. Hervé, P. Tiberghien and E. Robinet for the Société Française de Greffe de Moelle et de Therapie Cellulaire

HAEMOPOIESIS AND APLASIA

701 **Improved outcome of alternative donor bone marrow transplantation in children with severe aplastic anaemia using a conditioning regimen containing low-dose total body irradiation, cyclophosphamide and Campath**
G. S. Vassiliou, D. K. H. Webb, D. Pamphilon, S. Knapper and P. A. Veys

706 **Unrelated donor marrow transplantation in children with severe aplastic anaemia using cyclophosphamide, anti-thymocyte globulin and total body irradiation**
S. Kojima, J. Inaba, A. Yoshimi, Y. Takahashi, N. Watanabe, K. Kudo, K. Horibe, N. Maeda, K. Kato and T. Matsuyama

712 **Immune function in patients with Shwachman–Diamond syndrome**
Y. Dror, H. Ginzberg, I. Dalal, V. Cherepanov, G. Downey, P. Durie, C. M. Roifman and M. H. Freedman

RED CELLS

Short report 718 **A novel multilocus genotyping assay to identify genetic predictors of stroke in sickle cell anaemia**
C. Hoppe, S. Cheng, M. Grow, A. Silbergleit, W. Klitz, E. Trachtenberg, H. Erlich, E. Vichinsky and L. Styles

TRANSFUSION

Short report 721 **Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura**
J. de la Rubia, F. Arriaga, D. Linares, L. Larrea, N. Carpio, M. L. Marty and M. A. Sanz

MOLECULAR BIOLOGY

724 **Cloning of the *Ly-6A* (Sca-1) gene locus and identification of a 3′ distal fragment responsible for high-level γ-interferon-induced expression *in vitro***
X. Ma, K.-W. Ling and E. Dzierzak

CORRESPONDENCE

731 **Relationship between immunological abnormalities and paroxysmal nocturnal haemoglobinuria-associated clones in myelodysplastic syndromes**
T. Okamoto, M. Okada, H. Takatsuka, H. Wada, Y. Fujimori and E. Kakishita

733 **DDAVP treatment in children with haemophilia B**
K. Kavakli, Y. Aydinok, D. Karapinar and C. Balkan

734 **Advanced-stage, chemorefractory lymphocyte-predominant Hodgkin's disease: long-term follow-up of allografting and monoclonal antibody therapy**
R. J. Lush, S. G. Jones and A. P. Haynes
736 **BOOK REVIEWS**
738 **ERRATA**

Volume 114, Issue 4, September-II 2001

IMAGES IN HAEMATOLOGY

739 **Targeting the dust**
M. Exner and I. Schwarzinger
740 **Purple toe syndrome following anticoagulant therapy**
K. Raj, B. Collins and S. Rangarajan

REVIEWS

741 **Anaplastic large cell lymphoma: pathological, molecular and clinical features**
B. Falini
761 **Pathogenesis of haemophagocytic lymphohistiocytosis**
M. Aricò, C. Danesino, D. Pende and L. Moretta

HISTORICAL REVIEW

770 **The immune haemolytic anaemias: a century of exciting progress in understanding**
J. Dacie

HAEMATOLOGICAL MALIGNANCY

786 **Interphase fluorescence *in situ* hybridization and spectral karyotyping reveals hidden genetic aberrations in children with acute lymphoblastic leukaemia and a normal banded karyotype**
A. Nordgren, J. Schoumans, S. Söderhäll, M. Nordenskjöld and E. Blennow
794 **Pharmacokinetics of native *Escherichia coli* asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment**
H.-J. Müller, R. Beier, L. Löning, R. Blütters-Sawatzki, W. Dörffel, E. Maass, S. Müller-Weihrich, H.-G. Scheel-Walter, F. Scherer, K. Stahnke, M. Schrappe, A. Horn, K. Lümkemann and J. Boos
800 **Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone**
N. Di Gaetano, Y. Xiao, E. Erba, R. Bassan, A. Rambaldi, J. Golay and M. Introna
810 **Transient pancytopenia preceding acute lymphoblastic leukaemia (pre-ALL) precipitated by parvovirus B19**
E. D. Heegaard, H. O. Madsen and K. Schmiegelow
814 **Differentiation of human acute myeloid leukaemia cells in primary culture in response to cotylenin A, a plant growth regulator**
K. Yamada, Y. Honma, K.-i. Asahi, T. Sassa, K.-i. Hino and S. Tomoyasu
822 **Results of autologous stem cell transplant in multiple myeloma patients with renal failure**
A. Badros, B. Barlogie, E. Siegel, J. Roberts, C. Langmaid, M. Zangari, R. Desikan, M. J. Shaver, A. Fassas, S. McConnell, F. Muwalla, Y. Barri, E. Anaissie, N. Munshi and G. Tricot

Short reports

830 **Dendritic cells in acute promyelocytic leukaemia**
G. M. Rigolin, M. D. Porta, R. Bigoni, A. Tieghi, A. Cuneo and G. Castoldi

834 **Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia**
J. Ooi, T. Iseki, H. Nagayama, A. Tomonari, K. Ito, N. Shirafuji, A. Tojo, K. Tani and S. Asano

PLATELETS, HAEMOSTASIS AND THROMBOSIS

837 **Protein A sepharose immunoadsorption: immunological and haemostatic effects in two cases of acquired haemophilia**
B. Guillet, F. Kriaa, M. G. Huysse, V. Proulle, C. George, G. Tchernia, R. D'Oiron, Y. Laurian, B. Charpentier, T. Lambert and M. Dreyfus

845 **Increased lipid peroxidation correlates with platelet activation but not with markers of endothelial cell and blood coagulation activation in patients with antiphospholipid antibodies**
M. E. Martinuzzo, R. R. Forastiero, L. Kordich and L. O. Carreras

852 **The inhibition of platelet aggregation and blood coagulation by *Micropechis ikaheka* venom**
I. B. Sundell, R. D. G. Theakston, A. S. Kamiguti, R. J. Harris, A. T. Treweeke, G. D. Laing, J. W. Fox, D. A. Warrell and M. Zuzel

861 **Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies**
M. Ling, E. M. Duncan, S. E. Rodgers, A. A. Somogyi, G. A. Crabb, A. M. Street and J. V. Lloyd

Short reports

868 **A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders**
E. Castoldi, B. Lunghi, F. Mingozzi, P. Simioni, A. Girolami and F. Berniardi

871 **Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency**
R. van Wujk, M. C. Montefusco, S. Duga, R. Asselta, W. van Solinge, M. Malcovati, M. L. Tenchini and P. M. Mannucci

875 **Severe factor XI deficiency caused by compound heterozygosity for the type III mutation and a novel insertion in exon 9 (codons 324/325 +G)**
A. Dossenbach-Glaninger, W. Krugluger, K. Schrattbauer, S. Eder and P. Hopmeier

878 **Inferior vena cava malformation as a risk factor for deep venous thrombosis in the young**
Y.-L. Chee, D. J. Culligan and H. G. Watson

LEUCOCYTES

Short report

881 **Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis**
J. M. Foran, A. J. Norton, I. N. M. Micallef, D. C. Taussig, J. A. L. Amess, A. Z. S. Rohatiner and T. A. Lister

HAEMOPOIESIS

884 **Intracellular Fas ligand is elevated in T lymphocytes in severe aplastic anaemia**
A. Luther-Wyrsch, C. Nissen and A. Wodnar-Filipowicz

891 **The effect of treatment with Campath-1H in patients with autoimmune cytopenias**
F. Willis, J. C. W. Marsh, D. H. Bevan, S. B. Killick, G. Lucas, R. Griffiths, W. Ouwehand, G. Hale, H. Waldmann and E. C. Gordon-Smith

RED CELLS

899 **The role of heterocellular hereditary persistence of fetal haemoglobin in β^0-thalassaemia intermedia**
Y.-P. C. Chang, R. Littera, R. Garau, K. D. Smith, G. J. Dover, S. Iannelli, E. Cacace and L. Contu

907 **Glycoconjugate abnormalities in patients with congenital dyserythropoietic anaemia type I, II and III**
E. Zdebska, E. Gołaszewska, J. Fabijańska-Mitek, H. Schachter, H. Shalev, H. Tamary, H. Sandström, A. Wahlin and J. Kościelak

Short reports

914 **Prevalence of *HFE* mutations in people from North Africa living in southern France**
P. Aguilar-Martinez, M.-C. Picot, F. Becker, P. Boulot, F. Montoya, P. Mares, B. Bachelard, Y. Henry, J.-L. Delarbre, P. Sarda and J.-F. Schved

917 **Vitamin E correlates inversely with non-transferrin-bound iron in sickle cell disease**
S. S. Marwah, D. Wheelwright, A. D. Blann, C. Rea, R. Beresford, J. D. Phillips, J. Wright and D. Bareford

TRANSPLANTATION

920 **Early-acting cytokine-driven *ex vivo* expansion of mobilized peripheral blood $CD34^+$ cells generates post-mitotic offspring with preserved engraftment ability in non-obese diabetic/severe combined immunodeficient mice**
C. Herrera, J. Sánchez, A. Torres, C. Bellido, A. Rueda and M. A. Alvarez

931 **Disparity for the minor histocompatibility antigen HA-1 is associated with an increased risk of acute graft-versus-host disease (GvHD) but it does not affect chronic GvHD incidence, disease-free survival or overall survival after allogeneic human leucocyte antigen-identical sibling donor transplantation**
D. Gallardo, J. I. Aróstegui, A. Balas, A. Torres, D. Caballero, E. Carreras, S. Brunet, A. Jiménez, R. Mataix, D. Serrano, C. Vallejo, G. Sanz, C. Solano, M. Rodríguez-Luaces, J. Marín, J. Baro, C. Sanz, J. Román, M. González, J. Martorell, J. Sierra, C. Martín, R. de la Cámara and A. Grañena on behalf of the GvHD Subcommittee of the GETH (Grupo Español de trasplante hemapoyético)

937 **Analysis of $CD34^+$ cell subsets in stem cell harvests can more reliably predict rapidity and durability of engraftment than total $CD34^+$ cell dose, but steady state levels do not correlate with bone marrow reserve**
G. Pratt, A. C. Rawstron, A. E. English, R. J. Johnson, A. S. Jack, G. J. Morgan and G. M. Smith

944 **Intravenous busulphan for conditioning before autologous or allogeneic human blood stem cell transplantation**
U. S. Schuler, U. D. Renner, F. Kroschinsky, C. Johne, A. Jenke, R. Naumann, M. Bornhäuser, H. J. Deeg and G. Ehninger

Short report

951 **Donor–recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor**
C. L. Balduini, F. Frassoni, P. Noris, C. Klersy, A. M. Iannone, A. Bacigalupo, G. Giorgiani, M. Di Pumpo and F. Locatelli

CORRESPONDENCE

954 **Central nervous system relapse of acute promyelocytic leukaemia in a patient with cerebral haemorrhage at diagnosis**
M. P. Macheta, J. Kok Shun and J. A. Liu Yin

955 **Pancytopenia after recombinant hepatitis B vaccine - an Indian case report**
K. Ashok Shenoy, M. R. Prabha Adhikari, M. Chakrapani, D. Shenoy and A. Pillai
956 **Treatment of patients with Factor VIII autoantiboodies by staphylococcal protein A-based immunoadsorption and immunosuppression**
B. Mansouri Taleghani and R. Grossmann
957 **Treatment of acquired Factor VIII autoantibodies by immunoadsorption**
M. Jansen, K. Derfler, W. H. Hörl and P. Knöbl
958 **Plasma cell subtypes in bone marrow biopsies from patients without plasma cell dyscrasia**
G. M. Markey, N. Connolly, T. C. M. Morris, P. Kettle and H. Foster
959 **Role of apolipoprotein E (APOE) polymorphism on left cardiac failure in homozygous β thalassaemic patients**
M. Ferrara, S. M. R. Matarese, M. Francese, B. Borrelli, L. Coppola, A. Coppola, D. Iarussi and L. Esposito
960 **Thrombopoietin concentration after orthotopic liver transplantation**
A. B. Mehta and A. K. Burroughs
961 **Reply to Mehta & Burroughs**
U. E. Nydegger
961 **The association of severe aplastic anaemia with the Philadelphia chromosome and the BCR/ABL transcript**
S. Sica, P. Chiusolo, M. Zollino, F. Sora, N. Piccirillo, L. Laurenti, G. Reddiconto and G. Leone
963 **BOOK REVIEWS**
965 **AUTHOR AND KEYWORD INDEXES FOR VOLUME 114**